Encontrado 1 documento, a visualizar página 1 de 1
Ordenado por
Data
ir para a página:
1
AT LAST! It was not a progression!
Paulinetti Camara, Raquel; Lopes, Kelly; Barbosa, Miguel; Sucena, Inês; Simão, Carla; Mota, Paulo; Matias, Dina; Sequeira, Telma; Almodovar, TeresaIntroduction: Nivolumab is approved in Portugal for non-small cell metastatic lung cancer, as one of the indications, after progressing on chemotherapy. As an immune checkpoint inhibitor (ICI) immune-related adverse events (irAE) are possible reactions. Case report: A 64-year-old man with stage III lung adenocarcinoma who progressed after chemoradiotherapy and first line metastatic chemotherapy started nivoluma...
Data: 2024
|
Origem: THORAC (Thoracic Cancer Journal)